Altimmune Stock Price, News & Analysis

Altimmune (Nasdaq: ALT) has completed enrollment in its Phase 2b IMPACT trial, evaluating pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). The trial includes approximately 190 subjects, with top-line efficacy data expected in Q2 2025. An End-of-Phase 2 Meeting with the FDA for the obesity program is scheduled for early November 2024.

The company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications starting in Q4 2024. Altimmune aims to expand pemvidutide's differentiation in the metabolic disease space and enhance its long-term value proposition. The IMPACT trial is notable as the first incretin-based study to evaluate a biopsy-driven fibrosis endpoint at 24 weeks.

Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor agonist:

1. Lean loss ratio of only 21.9%, indicating excellent preservation of lean mass.
2. Even better lean mass preservation in subjects aged 60+, with a lean loss ratio of 19.9%.
3. 25.6% reduction in visceral adipose tissue (VAT) at the 2.4mg dose, compared to 20.1% loss in subcutaneous adipose tissue.

These results suggest pemvidutide's potential in reducing fall and fracture risks, especially in older adults, while also lowering cardiovascular disease risk through VAT reduction.

Altimmune (Nasdaq: ALT) announced that data from its Phase 2 MRI-based body composition sub-study of pemvidutide in overweight and obese subjects will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid. Pemvidutide, a novel GLP-1/glucagon dual receptor agonist, is being developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH) treatment.

The presentation, titled 'Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity,' will be given by Dr. Sarah Browne on September 10, 2024. Pemvidutide has shown promising results in clinical trials, demonstrating significant weight loss, reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure. The FDA has granted Fast Track designation for pemvidutide in MASH treatment.

Altimmune (Nasdaq: ALT) announced Q2 2024 financial results and provided a business update. Key highlights include:

• Presentations at major medical meetings supporting pemvidutide's differentiated profile in obesity and MASH
• Enrollment progressing in Phase 2b IMPACT trial of pemvidutide in MASH, with topline data expected in Q1 2025
• Cash position of $164.9 million as of June 30, 2024
• Data presented at ADA showing up to 15.6% weight loss at 48 weeks and class-leading lean mass preservation
• End-of-Phase 2 meeting with FDA expected in late Q3 2024
• Net loss of $24.6 million for Q2 2024, compared to $16.1 million in Q2 2023

Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced it will release its second quarter 2024 financial results on August 8, 2024. The company will also provide a business update during a conference call scheduled for 8:30 am E.T. on the same day. Investors can access the webcast live on Altimmune's Investor Relations website. Those wishing to join the call can register to receive dial-in numbers and a unique PIN. A replay of the call will be available on the Investor Relations website for up to three months after the event.

Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:

- Up to 68.5% relative reduction in liver fat content (LFC)
- Up to 55.6% of subjects achieved LFC normalization
- Significant improvements in body weight and liver inflammation markers
- 94.4% of subjects achieved ≥30% relative reduction in LFC
- Well-tolerated with 2.9% adverse event discontinuations

Pemvidutide is currently in a Phase 2b IMPACT trial for metabolic dysfunction-associated steatohepatitis (MASH), with results expected in Q1 2025.

Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, announced its participation in the Leerink Partners Therapeutics Forum on July 9 and 10, 2024, in Boston, MA. The company's management team will engage in one-on-one meetings with institutional investors. This forum will include panel discussions with leading physicians focusing on autoimmune and metabolic diseases. Altimmune aims to leverage these interactions to advance its strategic objectives and investor relations.

Altimmune (Nasdaq: ALT) announced the unexpected passing of their Chief Financial Officer, Richard Eisenstadt, on June 24, 2024. President and CEO Vipin K. Garg expressed deep sorrow on behalf of the company, highlighting Eisenstadt's leadership and personal qualities. While the search for his replacement is underway, the finance and accounting team will manage his responsibilities.

Altimmune presented data from its 48-week Phase 2 MOMENTUM trial of pemvidutide at the ADA’s 84th Scientific Sessions. The trial focused on pemvidutide, a GLP-1/glucagon dual receptor agonist for obesity treatment. Key findings show that 78.1% of weight loss was due to fat reduction, with only 21.9% from lean mass. The trial involved 391 subjects, achieving mean weight losses of 10.3%, 11.2%, 15.6%, and 2.2% for the 1.2 mg, 1.8 mg, 2.4 mg doses, and placebo, respectively. Additionally, pemvidutide improved serum lipids and blood pressure without notable cardiac events. These findings suggest that pemvidutide may offer a promising, long-term treatment for obesity.